CA2828072A1 - Indirect substrates for microorganisms metabolizing 1,2-propanediol - Google Patents
Indirect substrates for microorganisms metabolizing 1,2-propanediol Download PDFInfo
- Publication number
- CA2828072A1 CA2828072A1 CA2828072A CA2828072A CA2828072A1 CA 2828072 A1 CA2828072 A1 CA 2828072A1 CA 2828072 A CA2828072 A CA 2828072A CA 2828072 A CA2828072 A CA 2828072A CA 2828072 A1 CA2828072 A1 CA 2828072A1
- Authority
- CA
- Canada
- Prior art keywords
- rhamnose
- pectin
- fucose
- reuteri
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 title claims abstract description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 235000013772 propylene glycol Nutrition 0.000 title claims abstract description 20
- 239000000758 substrate Substances 0.000 title abstract description 14
- 244000005700 microbiome Species 0.000 title description 10
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 114
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 78
- 229920001277 pectin Polymers 0.000 claims abstract description 65
- 239000001814 pectin Substances 0.000 claims abstract description 63
- 235000010987 pectin Nutrition 0.000 claims abstract description 63
- 239000006041 probiotic Substances 0.000 claims abstract description 60
- 235000018291 probiotics Nutrition 0.000 claims abstract description 60
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract description 51
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 44
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract description 36
- 230000000694 effects Effects 0.000 claims abstract description 32
- 230000001965 increasing effect Effects 0.000 claims abstract description 7
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 65
- 241000894006 Bacteria Species 0.000 claims description 36
- 239000000126 substance Substances 0.000 claims description 34
- 230000000529 probiotic effect Effects 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 24
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 229920000855 Fucoidan Polymers 0.000 claims description 19
- 229930182830 galactose Natural products 0.000 claims description 17
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 16
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 16
- 230000002708 enhancing effect Effects 0.000 claims description 14
- 150000008266 deoxy sugars Chemical class 0.000 claims description 10
- 150000001720 carbohydrates Chemical class 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- 239000000370 acceptor Substances 0.000 description 21
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 19
- 230000004151 fermentation Effects 0.000 description 17
- 238000000855 fermentation Methods 0.000 description 17
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000002002 slurry Substances 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 229940001882 lactobacillus reuteri Drugs 0.000 description 8
- 235000013406 prebiotics Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000009754 rhamnogalacturonan I Substances 0.000 description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000008914 rhamnogalacturonan II Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CBDCDOTZPYZPRO-DEZHIRTDSA-N (2r,3r,4s,5s)-2,3,4,5-tetrahydroxyhexanal;hydrate Chemical compound O.C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O CBDCDOTZPYZPRO-DEZHIRTDSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 230000007366 host health Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 239000005717 Laminarin Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000010243 gut motility Effects 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 108010004621 phosphoketolase Proteins 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 210000004203 pyloric antrum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000227647 Fucus vesiculosus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001466453 Laminaria Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000673 dextrose monohydrate Drugs 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001200 fecal consistency Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/22—Processes using, or culture media containing, cellulose or hydrolysates thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/231—Pectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates generally to enhanced activity of certain probiotics. The increased efficacy is achieved by using certain substrate components that indirectly supply the probiotics with a specific source of energy. The substrate components are specifically designed to stimulate 1,2-propanediol production. The substrate is exemplified with rhamnose, fucose, pectin with a high percentage of rhamnose, and fucodian having a high percentage of fucose.
Description
INDIRECT SUBSTRATES FOR MICROORGANISMS
METABOLIZING 1,2-PROPANEDIOL
FIELD OF THE INVENTION
The present invention relates generally to enhancing the activity of certain probiotics in mammals. Moreover this invention relates to preparations comprising substrate components and certain probiotics, the substrate components being specifically designed to enhance the efficacy of said probiotics. The substrate components are selected to generate 1,2-propanediol, which uniquely most Lactobacillus reuteri strains can utilize as a source of energy and/or as an external electron acceptor.
BACKGROUND OF THE INVENTION
The Food and Agricultural Organization of the United Nations define probiotics as "live microorganisms which when administered in adequate amounts confer a health benefit on the host". Nowadays, a number of different bacteria are used as probiotics for example, lactic acid bacteria such as strains of Lactobacillus and Bifidobacterium.
The effectiveness of probiotics is strain-specific, and each strain may contribute to host health through different mechanisms. Different probiotics can prevent or inhibit the proliferation of pathogens, suppress production of virulence factors by pathogens, modulate the immune response in a pro-inflammatory or an anti-inflammatory way and influence the host in a number of other ways.
Prebiotics are defined as "non-digestible food ingredients that beneficially affect the host by selectively stimulating the growth and/or activity of one, or a limited number of bacteria in the colon that can improve the host health." Targets for prebiotics are usually bifidobacteria and lactobacilli; however, prebiotics are often not selective, and hence stimulation of beneficial genera or probiotic strains alone may be difficult to achieve. Since it is difficult to find a prebiotic that is selective for certain probiotics, the inventor of the present invention has discovered how to use specific substrate components (SSC) that indirectly will supply specific probiotics with a source of energy and/or an external electron acceptor that will increase the energy yield.
Lactobacillus reuteri is a heterofermentative lactic acid bacterium and is frequently found in the gastrointestinal tract of humans and other animals. L. reuteri is considered an indigenous organism of the human gastrointestinal tract and is for example present on the mucosa of the gastric corpus, gastric antrum, duodenum, and ileum. See, for example U.S.
Patent Nos. 5,439,678, 5,458,875, 5,534,253, 5,837,238, and 5,849,289. When L.
reuteri cells are grown under anaerobic conditions in the presence of glycerol, they produce the antimicrobial substance known as reuterin (B-hydroxy propionaldehyde). The ability to produce reuterin is due to the propanediol utilization (pdu) operon. The pdu operon is a metabolic machinery that also enables growth on 1,2-propanediol (PD). This pdu operon is a very important feature for L. reuteri when colonizing humans and exploiting the full potential of the bacteria. This machinery is rare among other lactobacilli and therefore those without the pdu-machinery are not able to grow on 1,2-PD and neither are they capable of using 1,2-PD as an electron acceptor.
Different L. reuteri strains have the ability to colonize the intestine, act as a diarrhea therapeutic agent, modulate the gut motility, function as an inhibitor of bacterial pathogens, immunologically modulate the gastrointestinal mucosa, function as an anti-inflammatory agent in the stomach etc.
In patent application W02009/151391, the pdu machinery of L. reuteri is primed with 1,2-PD or glycerol before freeze-drying the bacteria. With this manufacture design the freeze-dried pdu machinery of L. reuteri is primed with the capacity to make and store reuterin.
Emma Arskold et. al., Phosphoketolase Pathway Dominates in Lactobacillus reuteri ATCC 55730 Containing Dual Pathways for Glycolysis (Journal of Bacteriology, Jan 2008, p.
206-212) describes that growth performance of L. reuteri on glucose can be improved by adding fructose as an external electron acceptor. However nothing in this article teaches how to select certain SSCs based on their ability to indirectly supply certain probiotics with 1,2-PD, which may only be utilized by bacteria with the pdu-machinery.
A common problem with oral administration of probiotic bacteria is insufficient amounts and/or activity of the probiotic bacteria in locations of the intestinal tract where they will assert their effects. This may have as a consequence that the dosage of probiotic bacteria has to be increased and/or more frequent administration is needed and might also result in loss of activity. This leads to unnecessary costs, undesirable frequency of intake and/or decreased health benefits. In the present invention the local amounts and/or metabolic activity of for example L. reuteri is enhanced, leading for example to the possibility of lowering the dosage of the probiotic and further that site-directed health benefits are possible.
1,2-propanediol (1,2-PD) is a source of energy that can be locally produced by other coexisting microorganisms and utilized, possibly in combination with additional sugars, by certain probiotic species, e.g. L. reuteri. The inventor of the present invention has surprisingly discovered that those coexisting microbes can be stimulated to produce 1,2-PD
by oral administration of very selective SSCs and thereby indirectly enhance the activity of 1,2-PD
utilizing organisms such as L. reuteri.
Pectin is a polysaccharide from plant cell walls. Various pectic polysaccharides can be detected in the cell wall, including homogalacturonan (HG), xylogalacturonan (XGA), apiogalacturonan, rhamnogalacturonan I (RGI), and rhamnogalacturonan II
(RGII). The ratio between HG, XGA, RGI and RGII is variable, but typically HG is the most abundant polysaccharide constituting about 65% of the pectin, while RGI constitutes 20%
to 35%.
Pectin is resistant to human digestion, but is degraded to sugars and then further metabolized, for example to 1,2-propanediol, by bacteria in the small intestine and colon.
Pectin stimulates bacterial growth in the small intestine and in the colon.
Pectin is used as a remedy for diarrhea, is related to improved intestinal environment and is also known to have Fucoidan is a sulfated polysaccharide found mainly in various species of brown algae and brown seaweed such as mozuku, kombu, limu, moui, bladderwrack, wakame and hijiki, variant forms of fucoidan have also been found in animal species, including the sea cucumber.
Lynch MB et al., The effect of dietary Laminaria-derived laminarin and fucoidan on nutrient digestablility, nitrogen utilisation, intestinal microflora and volatile fatty acid laminarin and fucoidan diet of the weanling piglet on performance and selected faecal microbial populations (Livestock science 2010 September).
However it was not previously known to select, for example, pectin and fucoidan, or fractions thereof, based on the amounts of L-rhamnose and/or L-fucose in order to generate 1,2-PD through bacterial fermentation and to use such compositions with high deoxy sugar content, particularly high L-rhamnose and/or L-fucose content which will lead to high amounts of 1,2-PD thus indirectly supplying certain microorganism, for example L. reuteri with a source of energy and/or an external electron acceptor, which most other microbes are not able to utilize due to lack of the pdu machinery.
Patent application W02010/117274 relates to a carbohydrate which is able to induce a detectable increase of a C5 and/or a C6 Short Chain Fatty Acid (SCFA). The SCFA has a positive effect on the gastrointestinal health of the subject treated. The carbohydrate used comprises pectin. Even though they chose pectins that may comprise traces of rhamnose, they do not disclose how to select and use specific pectin high in L-rhamnose or L-fucose to indirectly supply probiotics with the pdu-machinery with a specific source of energy and/or an external electron acceptor thus enhancing their activity.
U.S. Patent No. 7,101,565 relates to a composition comprising a prebiotic and a probiotic. The prebiotic may comprise a pectin or pectic polysaccharide.
However it is not disclosed in this invention how to select certain pectins, or use combinations with pectin and L-rhamnose or L-fucose, that will generate high amounts of 1,2-PD in the gastrointestinal tract, beneficial for probiotics with the pdu machinery.
In U.S. Patent No. 5,902,578 an invention is disclosed that relates to a method of preventing diarrhea associated with infectious agents such as rotavirus, or diarrhea associated with antibiotic therapies by using Lactobacillus. However in this invention Lactobacillus is not associated with additional SSCs for better efficacy.
Nobody has hitherto disclosed how to enhance the health promoting effects of certain probiotics by administering SSCs, together with a probiotic, e.g. L. reuteri, to indirectly supply such probiotics with a unique source of energy and/or an external electron acceptor.
Oral administration of SSCs, with high content of L-rhamnose and/or L-fucose will secure the supply of 1,2-propanediol and thus indirectly supply certain prebiotics with a source of energy and/or an external electron acceptor. This will increase the local amounts of health promoting microorganisms, e.g. L. reuteri, and provide better efficacy, making site directed effects possible.
Even though it has previously been known to use for example pectin together with probiotics, it is not previously known how to select SSCs based on their ability to form 1,2-PD for the indirect supply of certain probiotics with a specific energy source and/or a specific external electron acceptor.
SUMMARY OF THE INVENTION
This invention discloses a method of enhancing the activity of certain probiotics and the manufacturing and use of products, which comprises substrate components and optionally a probiotic. The products of the present invention can be used to enhance the activity of for example L. reuteri in mammals. This product can be used for improving the host health.
Depending on the used probiotic strain, the product can be used for example to improve gastrointestinal health, improve immune-related health, treat and/or prevent diarrhea and constipation, normalize fecal consistency, improve gastrointestinal motility, treat and/or prevent infectious diseases, modulate inflammation and anti-pathogenic effect.
The increased efficacy of probiotics can be achieved by stimulating co-existing microbes to produce 1,2-propanediol (1,2-PD). The coexisting microbes are stimulated with certain specific substrate components (SSC) as described herein. The SSCs will ensure the presence of 1,2-PD in the gastro intestinal tract and indirectly supply certain beneficial organisms with 1,2-PD.
The ability to utilize 1,2-PD either as an energy source and/or as an external electron acceptor is unique for bacteria with the pdu-machinery and therefore the administration of SSCs will enhance the activity only of certain probiotics.
The SSCs can be administered together with the probiotics for enhancing the activity of the co-administered probiotics. The SSCs could also be administered alone, for example to increase the activity of previously administered probiotics.
1,2-PD, administered alone or generated by the SSCs, may further be combined with galacto-oligosaccharides (GOS) or other galactose containing saccharides to give an even better source of energy for the microorganisms.
Heterofermentative lactic acid bacteria produce lactate, ethanol and carbon dioxide using the phosphoketolase pathway (PKP). The PKP has poor energy yield compared to the Embden-Meyerhof pathway (EMP). This disadvantage can be compensated for by addition of external electron acceptors.
The inventor has surprisingly found out that by ensuring the presence of 1,2-propanediol in the gastrointestinal tract, the probiotics will simultaneously be supplied with a suitable external electron acceptor and thereby enhance the activity of the probiotic.
METABOLIZING 1,2-PROPANEDIOL
FIELD OF THE INVENTION
The present invention relates generally to enhancing the activity of certain probiotics in mammals. Moreover this invention relates to preparations comprising substrate components and certain probiotics, the substrate components being specifically designed to enhance the efficacy of said probiotics. The substrate components are selected to generate 1,2-propanediol, which uniquely most Lactobacillus reuteri strains can utilize as a source of energy and/or as an external electron acceptor.
BACKGROUND OF THE INVENTION
The Food and Agricultural Organization of the United Nations define probiotics as "live microorganisms which when administered in adequate amounts confer a health benefit on the host". Nowadays, a number of different bacteria are used as probiotics for example, lactic acid bacteria such as strains of Lactobacillus and Bifidobacterium.
The effectiveness of probiotics is strain-specific, and each strain may contribute to host health through different mechanisms. Different probiotics can prevent or inhibit the proliferation of pathogens, suppress production of virulence factors by pathogens, modulate the immune response in a pro-inflammatory or an anti-inflammatory way and influence the host in a number of other ways.
Prebiotics are defined as "non-digestible food ingredients that beneficially affect the host by selectively stimulating the growth and/or activity of one, or a limited number of bacteria in the colon that can improve the host health." Targets for prebiotics are usually bifidobacteria and lactobacilli; however, prebiotics are often not selective, and hence stimulation of beneficial genera or probiotic strains alone may be difficult to achieve. Since it is difficult to find a prebiotic that is selective for certain probiotics, the inventor of the present invention has discovered how to use specific substrate components (SSC) that indirectly will supply specific probiotics with a source of energy and/or an external electron acceptor that will increase the energy yield.
Lactobacillus reuteri is a heterofermentative lactic acid bacterium and is frequently found in the gastrointestinal tract of humans and other animals. L. reuteri is considered an indigenous organism of the human gastrointestinal tract and is for example present on the mucosa of the gastric corpus, gastric antrum, duodenum, and ileum. See, for example U.S.
Patent Nos. 5,439,678, 5,458,875, 5,534,253, 5,837,238, and 5,849,289. When L.
reuteri cells are grown under anaerobic conditions in the presence of glycerol, they produce the antimicrobial substance known as reuterin (B-hydroxy propionaldehyde). The ability to produce reuterin is due to the propanediol utilization (pdu) operon. The pdu operon is a metabolic machinery that also enables growth on 1,2-propanediol (PD). This pdu operon is a very important feature for L. reuteri when colonizing humans and exploiting the full potential of the bacteria. This machinery is rare among other lactobacilli and therefore those without the pdu-machinery are not able to grow on 1,2-PD and neither are they capable of using 1,2-PD as an electron acceptor.
Different L. reuteri strains have the ability to colonize the intestine, act as a diarrhea therapeutic agent, modulate the gut motility, function as an inhibitor of bacterial pathogens, immunologically modulate the gastrointestinal mucosa, function as an anti-inflammatory agent in the stomach etc.
In patent application W02009/151391, the pdu machinery of L. reuteri is primed with 1,2-PD or glycerol before freeze-drying the bacteria. With this manufacture design the freeze-dried pdu machinery of L. reuteri is primed with the capacity to make and store reuterin.
Emma Arskold et. al., Phosphoketolase Pathway Dominates in Lactobacillus reuteri ATCC 55730 Containing Dual Pathways for Glycolysis (Journal of Bacteriology, Jan 2008, p.
206-212) describes that growth performance of L. reuteri on glucose can be improved by adding fructose as an external electron acceptor. However nothing in this article teaches how to select certain SSCs based on their ability to indirectly supply certain probiotics with 1,2-PD, which may only be utilized by bacteria with the pdu-machinery.
A common problem with oral administration of probiotic bacteria is insufficient amounts and/or activity of the probiotic bacteria in locations of the intestinal tract where they will assert their effects. This may have as a consequence that the dosage of probiotic bacteria has to be increased and/or more frequent administration is needed and might also result in loss of activity. This leads to unnecessary costs, undesirable frequency of intake and/or decreased health benefits. In the present invention the local amounts and/or metabolic activity of for example L. reuteri is enhanced, leading for example to the possibility of lowering the dosage of the probiotic and further that site-directed health benefits are possible.
1,2-propanediol (1,2-PD) is a source of energy that can be locally produced by other coexisting microorganisms and utilized, possibly in combination with additional sugars, by certain probiotic species, e.g. L. reuteri. The inventor of the present invention has surprisingly discovered that those coexisting microbes can be stimulated to produce 1,2-PD
by oral administration of very selective SSCs and thereby indirectly enhance the activity of 1,2-PD
utilizing organisms such as L. reuteri.
Pectin is a polysaccharide from plant cell walls. Various pectic polysaccharides can be detected in the cell wall, including homogalacturonan (HG), xylogalacturonan (XGA), apiogalacturonan, rhamnogalacturonan I (RGI), and rhamnogalacturonan II
(RGII). The ratio between HG, XGA, RGI and RGII is variable, but typically HG is the most abundant polysaccharide constituting about 65% of the pectin, while RGI constitutes 20%
to 35%.
Pectin is resistant to human digestion, but is degraded to sugars and then further metabolized, for example to 1,2-propanediol, by bacteria in the small intestine and colon.
Pectin stimulates bacterial growth in the small intestine and in the colon.
Pectin is used as a remedy for diarrhea, is related to improved intestinal environment and is also known to have Fucoidan is a sulfated polysaccharide found mainly in various species of brown algae and brown seaweed such as mozuku, kombu, limu, moui, bladderwrack, wakame and hijiki, variant forms of fucoidan have also been found in animal species, including the sea cucumber.
Lynch MB et al., The effect of dietary Laminaria-derived laminarin and fucoidan on nutrient digestablility, nitrogen utilisation, intestinal microflora and volatile fatty acid laminarin and fucoidan diet of the weanling piglet on performance and selected faecal microbial populations (Livestock science 2010 September).
However it was not previously known to select, for example, pectin and fucoidan, or fractions thereof, based on the amounts of L-rhamnose and/or L-fucose in order to generate 1,2-PD through bacterial fermentation and to use such compositions with high deoxy sugar content, particularly high L-rhamnose and/or L-fucose content which will lead to high amounts of 1,2-PD thus indirectly supplying certain microorganism, for example L. reuteri with a source of energy and/or an external electron acceptor, which most other microbes are not able to utilize due to lack of the pdu machinery.
Patent application W02010/117274 relates to a carbohydrate which is able to induce a detectable increase of a C5 and/or a C6 Short Chain Fatty Acid (SCFA). The SCFA has a positive effect on the gastrointestinal health of the subject treated. The carbohydrate used comprises pectin. Even though they chose pectins that may comprise traces of rhamnose, they do not disclose how to select and use specific pectin high in L-rhamnose or L-fucose to indirectly supply probiotics with the pdu-machinery with a specific source of energy and/or an external electron acceptor thus enhancing their activity.
U.S. Patent No. 7,101,565 relates to a composition comprising a prebiotic and a probiotic. The prebiotic may comprise a pectin or pectic polysaccharide.
However it is not disclosed in this invention how to select certain pectins, or use combinations with pectin and L-rhamnose or L-fucose, that will generate high amounts of 1,2-PD in the gastrointestinal tract, beneficial for probiotics with the pdu machinery.
In U.S. Patent No. 5,902,578 an invention is disclosed that relates to a method of preventing diarrhea associated with infectious agents such as rotavirus, or diarrhea associated with antibiotic therapies by using Lactobacillus. However in this invention Lactobacillus is not associated with additional SSCs for better efficacy.
Nobody has hitherto disclosed how to enhance the health promoting effects of certain probiotics by administering SSCs, together with a probiotic, e.g. L. reuteri, to indirectly supply such probiotics with a unique source of energy and/or an external electron acceptor.
Oral administration of SSCs, with high content of L-rhamnose and/or L-fucose will secure the supply of 1,2-propanediol and thus indirectly supply certain prebiotics with a source of energy and/or an external electron acceptor. This will increase the local amounts of health promoting microorganisms, e.g. L. reuteri, and provide better efficacy, making site directed effects possible.
Even though it has previously been known to use for example pectin together with probiotics, it is not previously known how to select SSCs based on their ability to form 1,2-PD for the indirect supply of certain probiotics with a specific energy source and/or a specific external electron acceptor.
SUMMARY OF THE INVENTION
This invention discloses a method of enhancing the activity of certain probiotics and the manufacturing and use of products, which comprises substrate components and optionally a probiotic. The products of the present invention can be used to enhance the activity of for example L. reuteri in mammals. This product can be used for improving the host health.
Depending on the used probiotic strain, the product can be used for example to improve gastrointestinal health, improve immune-related health, treat and/or prevent diarrhea and constipation, normalize fecal consistency, improve gastrointestinal motility, treat and/or prevent infectious diseases, modulate inflammation and anti-pathogenic effect.
The increased efficacy of probiotics can be achieved by stimulating co-existing microbes to produce 1,2-propanediol (1,2-PD). The coexisting microbes are stimulated with certain specific substrate components (SSC) as described herein. The SSCs will ensure the presence of 1,2-PD in the gastro intestinal tract and indirectly supply certain beneficial organisms with 1,2-PD.
The ability to utilize 1,2-PD either as an energy source and/or as an external electron acceptor is unique for bacteria with the pdu-machinery and therefore the administration of SSCs will enhance the activity only of certain probiotics.
The SSCs can be administered together with the probiotics for enhancing the activity of the co-administered probiotics. The SSCs could also be administered alone, for example to increase the activity of previously administered probiotics.
1,2-PD, administered alone or generated by the SSCs, may further be combined with galacto-oligosaccharides (GOS) or other galactose containing saccharides to give an even better source of energy for the microorganisms.
Heterofermentative lactic acid bacteria produce lactate, ethanol and carbon dioxide using the phosphoketolase pathway (PKP). The PKP has poor energy yield compared to the Embden-Meyerhof pathway (EMP). This disadvantage can be compensated for by addition of external electron acceptors.
The inventor has surprisingly found out that by ensuring the presence of 1,2-propanediol in the gastrointestinal tract, the probiotics will simultaneously be supplied with a suitable external electron acceptor and thereby enhance the activity of the probiotic.
The SSCs of the present invention will selectively increase the growth of heterofermentative lactic acid bacteria, such as Lactobacillus reuteri, since they will provide the bacteria with a suitable electron acceptor enabling an enhanced activity.
L. reuteri are dependent on a good electron acceptor for growth in certain environments, and the inventor of the present invention has surprisingly found out that 1,2-propanediol will serve as a good electron acceptor and can be supplied by the administration of SSCs.
According to one aspect of the invention, a method is provided for enhancing the activity of probiotic bacteria having a pdu-operon, in the gastrointestinal tract of an individual, comprising administering a substance to said individual, which substance has the capacity to be metabolized to 1,2-propanediol in the gastrointestinal tract of said individual.
In an embodiment of the method, the substance comprises a deoxy sugar, which has the capacity to be metabolized to 1,2-propanediol in the gastrointestinal tract of said individual. In an embodiment, the deoxy sugar is rhamnose or fucose.
In an embodiment of the method, the substance comprises (a) rhamnose, (b) fucose, (c) pectin having a high percentage of rhamnose, (d) rhamnose in combination with pectin, (e) fucose in combination with pectin, (f) fucoidan having a high percentage of fucose, or (g) a combination of rhamnose, fucose and pectin.
In an embodiment of the invention, pectin having a high percentage of rhamnose is defined as comprising 5-15% rhamnose, such as 5, 6, 7, 8,9, 10, 11, 12, 13, 14 or 15%
rhamnose. In an embodiment of the invention, fucoidan having a high percentage of fucose is defined as comprising more than 15 % fucose.
In an embodiment of the method, the substance is administered simultaneously with bacteria having a pdu operon.
In a preferred embodiment of the invention, the substance is administered orally to the individual.
In another preferred embodiment of the method, the bacteria having the pdu-operon comprise Lactobacilllus reuteri.
In an embodiment of the method, the substance is administered to the individual at a daily dose of 0.25-25 g, preferably 1-2 g.
In an embodiment of the invention, the method further comprises simultaneously administering a galactooligosaccharide or other saccharides comprising galactose.
According to a second aspect of the invention, a substance is provided for use in enhancing the activity or increasing the growth of probiotic bacteria having a pdu-operon, in the gastrointestinal tract of an individual, which substance comprises a deoxy sugar that has the capacity to be metabolized to 1,2-propanediol in the gastrointestinal tract of said individual.
In an embodiment, the deoxy sugar is rhamnose or fucose.
In an embodiment of the invention, the substance comprises (a) rhamnose, (b) fucose, (c) pectin having a high percentage of rhamnose, (d) rhamnose in combination with pectin, (e) fucose in combination with pectin, (f) fucoidan having a high percentage of fucose, or (g) a combination of rhamnose, fucose and pectin.
In an embodiment of the invention, pectin having a high percentage of rhamnose is defined as comprising 5-15% rhamnose, such as 5, 6, 7, 8,9, 10, 11, 12, 13, 14 or 15%
rhamnose. In an embodiment of the invention, fucoidan having a high percentage of fucose is defined as comprising more than 15 fucose.
In a preferred embodiment relating to the substance, the bacteria having the pdu-operon are Lactobacilllus reuteri.
In an embodiment of the invention, the substance is administered to the individual at a daily dose of 0.25-25 g, preferably 1-2 g.
In an embodiment of the invention, the substance is for use in combination with galactooligosaccharides or other saccharides comprising galactose.
According to a third aspect of the invention, a composition is provided comprising (i) bacteria having a pdu-operon and (ii) a substance comprising a deoxy sugar, which deoxy sugar has the capacity to be metabolized to 1,2-propanediol in the gastrointestinal tract of an individual.
In an embodiment, the composition comprises bacteria having a pdu-operon, in combination with (a) rhamnose, (b) fucose, (c) pectin having a high percentage of rhamnose, (d) rhamnose in combination with pectin, (e) fucose in combination with pectin, (f) fucoidan having a high percentage of fucose, or (g) a combination of rhamnose, fucose and pectin.
In an embodiment of the invention, pectin having a high percentage of rhamnose is defined as comprising 5-15% rhamnose, such as 5, 6, 7, 8,9, 10, 11, 12, 13, 14 or 15%
rhamnose. In an embodiment of the invention, fucoidan having a high percentage of fucose is defined as comprising more than 15 % fucose.
In another embodiment, the composition further comprises galactooligosaccharides or other saccharides comprising galactose.
In an embodiment relating to the composition, the bacteria having the pdu-operon are Lactobacilllus reuteri.
L. reuteri are dependent on a good electron acceptor for growth in certain environments, and the inventor of the present invention has surprisingly found out that 1,2-propanediol will serve as a good electron acceptor and can be supplied by the administration of SSCs.
According to one aspect of the invention, a method is provided for enhancing the activity of probiotic bacteria having a pdu-operon, in the gastrointestinal tract of an individual, comprising administering a substance to said individual, which substance has the capacity to be metabolized to 1,2-propanediol in the gastrointestinal tract of said individual.
In an embodiment of the method, the substance comprises a deoxy sugar, which has the capacity to be metabolized to 1,2-propanediol in the gastrointestinal tract of said individual. In an embodiment, the deoxy sugar is rhamnose or fucose.
In an embodiment of the method, the substance comprises (a) rhamnose, (b) fucose, (c) pectin having a high percentage of rhamnose, (d) rhamnose in combination with pectin, (e) fucose in combination with pectin, (f) fucoidan having a high percentage of fucose, or (g) a combination of rhamnose, fucose and pectin.
In an embodiment of the invention, pectin having a high percentage of rhamnose is defined as comprising 5-15% rhamnose, such as 5, 6, 7, 8,9, 10, 11, 12, 13, 14 or 15%
rhamnose. In an embodiment of the invention, fucoidan having a high percentage of fucose is defined as comprising more than 15 % fucose.
In an embodiment of the method, the substance is administered simultaneously with bacteria having a pdu operon.
In a preferred embodiment of the invention, the substance is administered orally to the individual.
In another preferred embodiment of the method, the bacteria having the pdu-operon comprise Lactobacilllus reuteri.
In an embodiment of the method, the substance is administered to the individual at a daily dose of 0.25-25 g, preferably 1-2 g.
In an embodiment of the invention, the method further comprises simultaneously administering a galactooligosaccharide or other saccharides comprising galactose.
According to a second aspect of the invention, a substance is provided for use in enhancing the activity or increasing the growth of probiotic bacteria having a pdu-operon, in the gastrointestinal tract of an individual, which substance comprises a deoxy sugar that has the capacity to be metabolized to 1,2-propanediol in the gastrointestinal tract of said individual.
In an embodiment, the deoxy sugar is rhamnose or fucose.
In an embodiment of the invention, the substance comprises (a) rhamnose, (b) fucose, (c) pectin having a high percentage of rhamnose, (d) rhamnose in combination with pectin, (e) fucose in combination with pectin, (f) fucoidan having a high percentage of fucose, or (g) a combination of rhamnose, fucose and pectin.
In an embodiment of the invention, pectin having a high percentage of rhamnose is defined as comprising 5-15% rhamnose, such as 5, 6, 7, 8,9, 10, 11, 12, 13, 14 or 15%
rhamnose. In an embodiment of the invention, fucoidan having a high percentage of fucose is defined as comprising more than 15 fucose.
In a preferred embodiment relating to the substance, the bacteria having the pdu-operon are Lactobacilllus reuteri.
In an embodiment of the invention, the substance is administered to the individual at a daily dose of 0.25-25 g, preferably 1-2 g.
In an embodiment of the invention, the substance is for use in combination with galactooligosaccharides or other saccharides comprising galactose.
According to a third aspect of the invention, a composition is provided comprising (i) bacteria having a pdu-operon and (ii) a substance comprising a deoxy sugar, which deoxy sugar has the capacity to be metabolized to 1,2-propanediol in the gastrointestinal tract of an individual.
In an embodiment, the composition comprises bacteria having a pdu-operon, in combination with (a) rhamnose, (b) fucose, (c) pectin having a high percentage of rhamnose, (d) rhamnose in combination with pectin, (e) fucose in combination with pectin, (f) fucoidan having a high percentage of fucose, or (g) a combination of rhamnose, fucose and pectin.
In an embodiment of the invention, pectin having a high percentage of rhamnose is defined as comprising 5-15% rhamnose, such as 5, 6, 7, 8,9, 10, 11, 12, 13, 14 or 15%
rhamnose. In an embodiment of the invention, fucoidan having a high percentage of fucose is defined as comprising more than 15 % fucose.
In another embodiment, the composition further comprises galactooligosaccharides or other saccharides comprising galactose.
In an embodiment relating to the composition, the bacteria having the pdu-operon are Lactobacilllus reuteri.
In an embodiment of the composition, the substance is present in an amount such as to give a daily dose of 0.25-25 g, preferably 1-2 g.
According to another embodiment of the invention, the above-described composition is for use in enhancing the activity or increasing the growth of probiotic bacteria having a pdu-operon, in the gastrointestinal tract of an individual.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 is a graph showing growth of L. reuteri DSM 17938 in modified MRS
(with no glucose and citrate) with addition of 1,2-PD, galactose and a combination thereof DETAILED DESCRIPTION OF THE INVENTION AND
PREFERRED EMBODIMENTS THEREOF
The propanediol utilization (pdu) machinery of certain probiotics, among them for example Lactobacillus reuteri, enables growth on 1,2-propanediol (1,2-PD) as energy source and enables the ability to use 1,2-PD as an external electron acceptor.
The inventor of the present invention has surprisingly found a way of enhancing the activity of certain probiotics, using certain specific substrate components (SSCs) to indirectly support a specific probiotic organism with 1,2-PD that may be utilized as a source of energy or as an external electron acceptor.
The SSC is a substance. According to one embodiment of the invention, the substance is a substrate. In one embodiment, the substance consists of one component only. In another embodiment, the substance comprises two or more components.
Oral administration of these carefully selected SSCs stimulates coexisting microbes to produce 1,2-PD, which leads to locally produced 1,2-PD that can serve as a source of energy or as an external electron acceptor for certain microorganisms with the pdu-machinery, such as for example L. reuteri. The SSCs may be administered alone or together with the probiotics.
The presence of 1,2-PD will improve the growth conditions for certain microorganisms, moreover the inventor has found out that this can be further enhanced in the presence of galacto-oligosaccharides (GOS) or galactose, as can be seen in figure 1.
The SSCs of the present invention are chosen for their ability to indirectly support a specific probiotic with 1,2-PD, which may be used as energy source or as an external electron acceptor. The inventor of this invention has discovered that SSCs with high amounts of L-rhamnose or L-fucose are the most effective when used to enhance the activity of certain probiotics. Therefore the SSCs used in this invention are carefully selected with regards to the amounts of L-rhamnose and L-fucose.
Pectins, preferably certain fractions of pectin comprising high percentages of L-rhamnose, such as rhamnogalacturonan I and II, may be used as SSCs.
Preferably, these preferred fractions of pectin comprise 5-15% rhamnose. These fractions of pectin will, when degraded, result in more rhamnose than unfractionated pectin, which in the present text may be called pectin, ordinary pectin, or regular pectin. A certain daily dose of such preferred fractions of pectin, e.g. 2 g, will thus generate higher amounts of 1,2-PD as compared to the same daily dose (2 g) of regular pectin. Ordinary pectin could also be used, if administered together with L-rhamnose or L-fucose to indirectly and in the same manner be advantageous for certain microbes, e.g. L. reuteri. This combination will, in addition to 1,2-PD, also supply certain probiotics with other substrates, e.g. galactose, arabinose and galacturonic acid as a result of pectin degradation. The inventor of the present invention has shown that 1,2-PD in combination with certain pectin constituents, e.g. galactose, arabinose and galacturonic acid will generate a synergistic effect that enhances the utilization of 1,2-PD for certain probiotics, e.g. L. reuteri, as seen in figure 1.
Fucoidan, preferably certain fractions of fucoidan comprising high amounts of L-fucose may be used as SSCs in the present invention, and preferably these fractions of fucoidan comprise more than 15 % fucose. These fractions of fucoidan will, when degraded, result in more fucose than ordinary fucoidan and thus generate higher amounts of 1,2-PD.
L-rhamnose or L-fucose alone may also be used alone as SSCs of this invention.
Other SSCs, e.g. gums and other polysaccharides, can be used according to the present invention if they contain L-rhamnose, L-fucose or the like. Gums include, but are not limited to karaya gum and arabic gum. Further, some human milk oligosaccharides (HMO's) from human breast milk can be used as SSCs in the present invention.
Administering the SSCs of the present invention, either alone or together with a probiotic, e.g. L. reuteri, secures the supply of energy source for a specific probiotic and/or secures the presence of an external electron acceptor that will increase the energy yield, thus enhancing the local activity and efficacy of said probiotic.
In other embodiments and to support this effect it is further possible to add GOS or galactose in order to increase L. reuteri' s ability to utilize 1,2-PD.
Depending on the target indication, a number of L. reuteri strains can be used in the invention herein with different ability to colonize the intestine, act as a diarrhea therapeutic agent, modulate the gut motility, function as an inhibitor of bacterial pathogens, immunologically modulate the gastrointestinal mucosa, function as an anti-inflammatory agent in the stomach etc.
Pectin, L-rhamnose and L-fucose are resistant to human digestion, but are degraded to sugars and then further metabolized to for example 1,2-propanediol by co-existing microbes found in humans and available at certain locations of the human GI-tract, for example on the mucosa of the gastric corpus, gastric antrum, duodenum, and small intestine.
The invention herein therefore also makes it possible to favor site-directed effects in the human GI-tract. For example by using selected strains of L. reuteri as the probiotic, it is possible to enhance the anti-inflammatory effect of this strain in the ileum.
When using the described system of certain SSC' s in the present invention, with for example a specific strain of L. reuteri in humans with a very disturbed microflora, including a lack of normally found co-existing microbes able to convert the SSC to 1,2-PD, it is also another possibility of the invention herein to actively supply such co-existing microorganisms, e.g. Lactobacillus rhamnosus, to the recipient ensuring the efficacy of the administered SSCs.
The products comprising the SSCs of this invention, alone or in combination with certain probiotics are preferably formulated as a tablet, capsule, powder sachet or the like.
The product can be a food-supplement, a pharmaceutical product or the like. In such a product, the amount of probiotic feed should be in an amount sufficient to give the wanted effect of the specific strain, now also considering the enhanced effect by the SSC. Such levels are typically, but not limited to 10E+4 CFU to 10E+11 CFU per day, preferably in the range of 10E+6 CFU to 10E+9 CFU of L. reuteri.
The amount of the SSC should be in the range of 0.25 to 25 grams (g) per day when using pectins with high amounts of L-rhamnose and/or L-fucose. When using a combination of regular pectin with separate L-rhamnose and/or L-fucose, the total amount of SSCs should be in the range of 0.25 to 25g per day. In both cases, the daily dose of 0.25-25 g may for example be 0.25, 0.5, 1, 1.5, 2, 5, 10, 15,20 or 25 g, preferably 1-2 g, such as 1, 1.25, 1.5, 1.75 or 2 g.. The ratio between the regular pectin and either one of L-rhamnose or L-fucose, or the combination thereof, should be in the range of 95:5 to 0:100, but preferably 80:20 to 20:80 and even more preferably 70:30.
Another option when using the invention herein is to alternatively feed the SSC and the probiotic together, and at one or more occasions following the first feeding to feed only the SSC in a kind of shuttle program to lower the cost of treatment.
It is essential for this invention that the probiotics used have the pdu-machinery, since this is essential for the ability to use 1,2-PD as a source of energy and/or as an external electron acceptor. Therefore in another embodiment of the invention the pdu machinery of the probiotics is primed with 1,2-PD during the production of the probiotic strain for enhanced efficacy. This is done by adding 1,2-PD or glycerol and possibly cobalt or vitamin B-12 (since vitamin B-12 and cobalt are important for reuterin production) at the start of the fermentation step when culturing the bacteria. With this manufacture design, the freeze-dried bacteria to be used in the next step are better prepared to more quickly activate the pdu-machinery. This enhanced efficacy of the pdu machinery will in turn enhance the efficacy of the administered SSC of the present invention. Another way of enhancing the efficacy of the administered SSCs is to combine them with GOS or galactose, and the inventor has shown that the combination of 1,2-PD and galactose has an unexpected benefit on L.
reuteri' s growth.
Since numerous modifications and changes will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and operation shown and described, and accordingly, all suitable modifications and equivalents may be resorted to, falling within the scope of the invention as defined by the appended claims.
Manufacture of a sachet containing a composition of L. reuteri together with pectin, rhamnose and galacto-oligosaccharides.
The composition is made of:
L. reuteri DSM 17938: 10E+8 CFU / sachet Pectin (GENU pectin (citrus) type USP/200, CP Kelco France SARL, France): 840 mg / sachet L-rhamnose : (Rhamnose monohydrate L-(+), Kaden Biochemicals GmbH, Hamburg, Germany) 360 mg / sachet GOS15 (VIVINAL , FrieslandCampina Domo, The Netherlands) 800 mg / sachet The composition is filled at ambient temperature into aluminum foil bags as known in the art with desiccant (10 cm x 12 cm, using packaging material PET12/PE/ALU
12/PE/PE+desiccant/PE from Alcan) in a LAF bench (Holten Laminair Model S-2010 1.2 from Heto-Holten A/S, Denmark). To each bag, 2 g of powder with L. reuteri, pectin, L-rhamnose and galacto-oligosaccharides is added using the balance XP-600 from Denver Instrument GmbH, Germany. The filled aluminum foil bags are then heat sealed with the film sealing device model F460/2 from Kettenbaum Folienschweisstechnik GmbH & Co.
KG, Germany.
Manufacture of a sachet containing a composition of L. reuteri together with rhamnose.
The composition is made of:
2 g L-rhamnose: (Rhamnose monohydrate L-(+), Kaden Biochemicals GmbH, Hamburg, Germany)) containing 10E+8 CFU L. reuteri DSM 17938 / sachet The composition is filled into aluminum foil bags as in Example 1.
Manufacture of a sachet containing a composition of L. reuteri together with galacto-oligosaccharides and rhamnose.
The composition is made of:
1 g GOS15 (VIVINAL , FrieslandCampina Domo, The Netherlands) and 1 g L-rhamnose: (Rhamnose monohydrate L-(+), Kaden Biochemicals GmbH, Hamburg, Germany) containing 10E+8 CFU L. reuteri DSM 17938 / sachet The composition is filled into aluminum foil bags as in Example 1.
Manufacture of a primed L. reuteri strain This example describes how to manufacture a freeze-dried powder of L. reuteri with activated pdu-machinery. The primed L. reuteri strain can then be used when producing the sachets of examples 1-3.
Fermentation medium composition Dextrose mono hydrate 60 g/1 Yeast extract KAV 20 g/1 Peptone Type PS (of pig origin) 20 g/1 Di ammonium hydrogen citrate 5 g/1 Sodium acetate (x 3 H20) 4.7 g/1 Di potassium hydrogen phosphate 2 g/1 Tween80 0.5 g/1 Silibione (anti foam) 0.14 g/1 Magnesium sulphate 0.10 g/1 Manganese sulphate 0.03 g/1 Zinc sulphate hepta hydrate 0.01 g/1 Water q.s.
Centrifuge medium Peptone 0-24 Orthana (of pig origin) Cry oprotectants Lactose (of bovine origin) 33 %
Gelatin hydrolysate (of bovine origin) 22 %
Sodium glutamate 22 %
Maltodextrin 11 %
Ascorbic acid 11 %
Production steps of freeze dried Lactobacillus reuteri powder 1. Twenty ml of the fermentation medium is inoculated with 0.6 ml of freeze-dried Lactobacillus reuteri powder from a working cell bank vial. The fermentation is performed in a bottle at 37 C for 18 ¨20 hours without stirring or pH control i.e. static.
2. Two 1-liter flasks of the fermentation medium are inoculated with 9 ml cell slurry (from step 1) per liter of medium. The fermentation is performed at 37 C for 20 ¨22 hours without stirring or pH control i.e. static.
3. The two one liter cell slurries from step no. 2 are used to inoculate the 600-liter vessel containing 600 liters fermentation medium. The fermentation is performed at 37 C for 13 hours with stirring and pH control. At the start of the fermentation the pH
is 6.5. The pH
control starts when the pH drops below 5.4 using a 20% sodium hydroxide solution. The pH
control is set to pH 5.5.
4. The fourth and final fermentation step is performed in a 15,000-liter vessel with the inoculation from step no. 3. The fermentation is performed at 37 C for 9 to 12 hours with stirring and pH control. At the start of the fermentation the pH is 6.5. The pH control starts when the pH drops below 5.4 using a 20% sodium hydroxide solution. The pH
control is set to pH 5.5. 100 mM glycerol is added in the final phase of the fermentation, just before the culture reaches the stationary phase. The fermentation is complete when the culture reaches the stationary phase, which can be seen by the reduction of the addition of the sodium hydroxide solution. Roughly 930 liters of the sodium hydroxide solution is added to the 10,200 liters of media and 600 liters of inoculum during the fermentation.
The cell slurry from the final fermentation (step 4) is separated at 10 C
twice in a continuous centrifuge from Alfa Laval. By the first centrifugation the volume of the cell slurry is reduced from roughly 11,730 liters to 1200 liters. This volume is washed with 1200 liters of a peptone (Peptone 0-24, Orthana) solution in a 3000-liter vessel and is separated again before the mixing with the cryoprotectants (see below). The washing step with peptone is performed to avoid any freezing-point reduction in the freeze-drying process.
By the second centrifugation the volume of the cell slurry is reduced to 495 liters. This volume is mixed with 156 kg of the cryoprotectant solution to reach roughly 650 liters of the cell slurry.
The cell slurry is pumped to a 1000-liter vessel. The vessel is then transported to the freeze-drying plant.
At the freeze-drying plant, exactly 2 liters of the cell slurry is poured on each plate in the freeze dryer. The maximum capacity of the freeze dryer is 600 liters and all excessive cell slurry volume is thrown away.
The cell slurry of Lactobacillus reuteri has a dry matter content of 18 % and is freeze dried for four to five days.
During the freeze-drying process, the pressure in the process is between 0.176 mbar and 0.42 mbar. The vacuum pump is started when the pressure reaches 0.42 mbar.
The PRT
(pressurizing test) is used to determine when the process is complete. If the PRT or the increase of pressure is less then 0.02 mbar after 120 seconds, the process is stopped.
Combination of 1,2-PD and galactose generates a synergistic effect enhancing the activity of L. reuteri L. reuteri DSM 17938 was grown in modified MRS broth (with no glucose and citrate) with addition of 1,2-PD (0.3%), galactose (0.3%) or a combination of the two. The bacteria were grown for 24 h at 37 C. L. reuteri grown in the presence of both 1,2-PD and galactose surprisingly showed a significantly higher growth than the growth on the separate substances as seen in figure 1.
Example of shuttle program to be fed Thanks to the enhanced activity of L. reuteri induced by the SSCs described in this application it is possible to alternate the sachets of example 1 (sachet A) with sachets where L.
reuteri is excluded but otherwise manufactured according to example 1 (sachet B) in a shuttle program. This shuttle program does not reduce the efficiency of L. reuteri and may lower the treatment cost.
Sachet A is administered to the recipient at day 1, at day 2 and 3 the recipient is given sachet B. This administration scheme is repeated during the whole treatment period.
Intestinal colonization in vivo in humans A comparison between the intestinal colonization by L. reuteri alone and the same L.
reuteri administered together with SSC is made in a clinical study. 12 healthy volunteers are divided into two groups (A and B) with 6 participants in each group. Group A
receives the powder sachets of example 1, containing a composition of L. reuteri together with SSCs in the form of pectin, rhamnose and galacto-oligosaccharides. Group B receives the same L. reuteri strain but none of the above SSCs. Both groups are given 10E+8 CFU of L.
reuteri per day during 60 days. The quantitative evaluation of intestinal colonization by strains given alone or together with the SSCs is made by fecal sample examination at the beginning of the study, and after 30 and 60 days of the treatment period. Fecal L. reuteri is counted and the fecal amounts of group A and B are compared.
A significant increase in the fecal amounts of L. reuteri is seen in patients where L.
reuteri is administered together with SSCs, compared to patients where L.
reuteri is administered alone, as seen in table 1. The values are given as the average logio CFU per gram of feces SEM.
Table 1 study group L. reuteri count (n) before day 30 day 60 group A (6) N.D. 5.5 0.2 5.8 0.3 group B (6) N.D. 4.2 0.3 4.5 0.4
According to another embodiment of the invention, the above-described composition is for use in enhancing the activity or increasing the growth of probiotic bacteria having a pdu-operon, in the gastrointestinal tract of an individual.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 is a graph showing growth of L. reuteri DSM 17938 in modified MRS
(with no glucose and citrate) with addition of 1,2-PD, galactose and a combination thereof DETAILED DESCRIPTION OF THE INVENTION AND
PREFERRED EMBODIMENTS THEREOF
The propanediol utilization (pdu) machinery of certain probiotics, among them for example Lactobacillus reuteri, enables growth on 1,2-propanediol (1,2-PD) as energy source and enables the ability to use 1,2-PD as an external electron acceptor.
The inventor of the present invention has surprisingly found a way of enhancing the activity of certain probiotics, using certain specific substrate components (SSCs) to indirectly support a specific probiotic organism with 1,2-PD that may be utilized as a source of energy or as an external electron acceptor.
The SSC is a substance. According to one embodiment of the invention, the substance is a substrate. In one embodiment, the substance consists of one component only. In another embodiment, the substance comprises two or more components.
Oral administration of these carefully selected SSCs stimulates coexisting microbes to produce 1,2-PD, which leads to locally produced 1,2-PD that can serve as a source of energy or as an external electron acceptor for certain microorganisms with the pdu-machinery, such as for example L. reuteri. The SSCs may be administered alone or together with the probiotics.
The presence of 1,2-PD will improve the growth conditions for certain microorganisms, moreover the inventor has found out that this can be further enhanced in the presence of galacto-oligosaccharides (GOS) or galactose, as can be seen in figure 1.
The SSCs of the present invention are chosen for their ability to indirectly support a specific probiotic with 1,2-PD, which may be used as energy source or as an external electron acceptor. The inventor of this invention has discovered that SSCs with high amounts of L-rhamnose or L-fucose are the most effective when used to enhance the activity of certain probiotics. Therefore the SSCs used in this invention are carefully selected with regards to the amounts of L-rhamnose and L-fucose.
Pectins, preferably certain fractions of pectin comprising high percentages of L-rhamnose, such as rhamnogalacturonan I and II, may be used as SSCs.
Preferably, these preferred fractions of pectin comprise 5-15% rhamnose. These fractions of pectin will, when degraded, result in more rhamnose than unfractionated pectin, which in the present text may be called pectin, ordinary pectin, or regular pectin. A certain daily dose of such preferred fractions of pectin, e.g. 2 g, will thus generate higher amounts of 1,2-PD as compared to the same daily dose (2 g) of regular pectin. Ordinary pectin could also be used, if administered together with L-rhamnose or L-fucose to indirectly and in the same manner be advantageous for certain microbes, e.g. L. reuteri. This combination will, in addition to 1,2-PD, also supply certain probiotics with other substrates, e.g. galactose, arabinose and galacturonic acid as a result of pectin degradation. The inventor of the present invention has shown that 1,2-PD in combination with certain pectin constituents, e.g. galactose, arabinose and galacturonic acid will generate a synergistic effect that enhances the utilization of 1,2-PD for certain probiotics, e.g. L. reuteri, as seen in figure 1.
Fucoidan, preferably certain fractions of fucoidan comprising high amounts of L-fucose may be used as SSCs in the present invention, and preferably these fractions of fucoidan comprise more than 15 % fucose. These fractions of fucoidan will, when degraded, result in more fucose than ordinary fucoidan and thus generate higher amounts of 1,2-PD.
L-rhamnose or L-fucose alone may also be used alone as SSCs of this invention.
Other SSCs, e.g. gums and other polysaccharides, can be used according to the present invention if they contain L-rhamnose, L-fucose or the like. Gums include, but are not limited to karaya gum and arabic gum. Further, some human milk oligosaccharides (HMO's) from human breast milk can be used as SSCs in the present invention.
Administering the SSCs of the present invention, either alone or together with a probiotic, e.g. L. reuteri, secures the supply of energy source for a specific probiotic and/or secures the presence of an external electron acceptor that will increase the energy yield, thus enhancing the local activity and efficacy of said probiotic.
In other embodiments and to support this effect it is further possible to add GOS or galactose in order to increase L. reuteri' s ability to utilize 1,2-PD.
Depending on the target indication, a number of L. reuteri strains can be used in the invention herein with different ability to colonize the intestine, act as a diarrhea therapeutic agent, modulate the gut motility, function as an inhibitor of bacterial pathogens, immunologically modulate the gastrointestinal mucosa, function as an anti-inflammatory agent in the stomach etc.
Pectin, L-rhamnose and L-fucose are resistant to human digestion, but are degraded to sugars and then further metabolized to for example 1,2-propanediol by co-existing microbes found in humans and available at certain locations of the human GI-tract, for example on the mucosa of the gastric corpus, gastric antrum, duodenum, and small intestine.
The invention herein therefore also makes it possible to favor site-directed effects in the human GI-tract. For example by using selected strains of L. reuteri as the probiotic, it is possible to enhance the anti-inflammatory effect of this strain in the ileum.
When using the described system of certain SSC' s in the present invention, with for example a specific strain of L. reuteri in humans with a very disturbed microflora, including a lack of normally found co-existing microbes able to convert the SSC to 1,2-PD, it is also another possibility of the invention herein to actively supply such co-existing microorganisms, e.g. Lactobacillus rhamnosus, to the recipient ensuring the efficacy of the administered SSCs.
The products comprising the SSCs of this invention, alone or in combination with certain probiotics are preferably formulated as a tablet, capsule, powder sachet or the like.
The product can be a food-supplement, a pharmaceutical product or the like. In such a product, the amount of probiotic feed should be in an amount sufficient to give the wanted effect of the specific strain, now also considering the enhanced effect by the SSC. Such levels are typically, but not limited to 10E+4 CFU to 10E+11 CFU per day, preferably in the range of 10E+6 CFU to 10E+9 CFU of L. reuteri.
The amount of the SSC should be in the range of 0.25 to 25 grams (g) per day when using pectins with high amounts of L-rhamnose and/or L-fucose. When using a combination of regular pectin with separate L-rhamnose and/or L-fucose, the total amount of SSCs should be in the range of 0.25 to 25g per day. In both cases, the daily dose of 0.25-25 g may for example be 0.25, 0.5, 1, 1.5, 2, 5, 10, 15,20 or 25 g, preferably 1-2 g, such as 1, 1.25, 1.5, 1.75 or 2 g.. The ratio between the regular pectin and either one of L-rhamnose or L-fucose, or the combination thereof, should be in the range of 95:5 to 0:100, but preferably 80:20 to 20:80 and even more preferably 70:30.
Another option when using the invention herein is to alternatively feed the SSC and the probiotic together, and at one or more occasions following the first feeding to feed only the SSC in a kind of shuttle program to lower the cost of treatment.
It is essential for this invention that the probiotics used have the pdu-machinery, since this is essential for the ability to use 1,2-PD as a source of energy and/or as an external electron acceptor. Therefore in another embodiment of the invention the pdu machinery of the probiotics is primed with 1,2-PD during the production of the probiotic strain for enhanced efficacy. This is done by adding 1,2-PD or glycerol and possibly cobalt or vitamin B-12 (since vitamin B-12 and cobalt are important for reuterin production) at the start of the fermentation step when culturing the bacteria. With this manufacture design, the freeze-dried bacteria to be used in the next step are better prepared to more quickly activate the pdu-machinery. This enhanced efficacy of the pdu machinery will in turn enhance the efficacy of the administered SSC of the present invention. Another way of enhancing the efficacy of the administered SSCs is to combine them with GOS or galactose, and the inventor has shown that the combination of 1,2-PD and galactose has an unexpected benefit on L.
reuteri' s growth.
Since numerous modifications and changes will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and operation shown and described, and accordingly, all suitable modifications and equivalents may be resorted to, falling within the scope of the invention as defined by the appended claims.
Manufacture of a sachet containing a composition of L. reuteri together with pectin, rhamnose and galacto-oligosaccharides.
The composition is made of:
L. reuteri DSM 17938: 10E+8 CFU / sachet Pectin (GENU pectin (citrus) type USP/200, CP Kelco France SARL, France): 840 mg / sachet L-rhamnose : (Rhamnose monohydrate L-(+), Kaden Biochemicals GmbH, Hamburg, Germany) 360 mg / sachet GOS15 (VIVINAL , FrieslandCampina Domo, The Netherlands) 800 mg / sachet The composition is filled at ambient temperature into aluminum foil bags as known in the art with desiccant (10 cm x 12 cm, using packaging material PET12/PE/ALU
12/PE/PE+desiccant/PE from Alcan) in a LAF bench (Holten Laminair Model S-2010 1.2 from Heto-Holten A/S, Denmark). To each bag, 2 g of powder with L. reuteri, pectin, L-rhamnose and galacto-oligosaccharides is added using the balance XP-600 from Denver Instrument GmbH, Germany. The filled aluminum foil bags are then heat sealed with the film sealing device model F460/2 from Kettenbaum Folienschweisstechnik GmbH & Co.
KG, Germany.
Manufacture of a sachet containing a composition of L. reuteri together with rhamnose.
The composition is made of:
2 g L-rhamnose: (Rhamnose monohydrate L-(+), Kaden Biochemicals GmbH, Hamburg, Germany)) containing 10E+8 CFU L. reuteri DSM 17938 / sachet The composition is filled into aluminum foil bags as in Example 1.
Manufacture of a sachet containing a composition of L. reuteri together with galacto-oligosaccharides and rhamnose.
The composition is made of:
1 g GOS15 (VIVINAL , FrieslandCampina Domo, The Netherlands) and 1 g L-rhamnose: (Rhamnose monohydrate L-(+), Kaden Biochemicals GmbH, Hamburg, Germany) containing 10E+8 CFU L. reuteri DSM 17938 / sachet The composition is filled into aluminum foil bags as in Example 1.
Manufacture of a primed L. reuteri strain This example describes how to manufacture a freeze-dried powder of L. reuteri with activated pdu-machinery. The primed L. reuteri strain can then be used when producing the sachets of examples 1-3.
Fermentation medium composition Dextrose mono hydrate 60 g/1 Yeast extract KAV 20 g/1 Peptone Type PS (of pig origin) 20 g/1 Di ammonium hydrogen citrate 5 g/1 Sodium acetate (x 3 H20) 4.7 g/1 Di potassium hydrogen phosphate 2 g/1 Tween80 0.5 g/1 Silibione (anti foam) 0.14 g/1 Magnesium sulphate 0.10 g/1 Manganese sulphate 0.03 g/1 Zinc sulphate hepta hydrate 0.01 g/1 Water q.s.
Centrifuge medium Peptone 0-24 Orthana (of pig origin) Cry oprotectants Lactose (of bovine origin) 33 %
Gelatin hydrolysate (of bovine origin) 22 %
Sodium glutamate 22 %
Maltodextrin 11 %
Ascorbic acid 11 %
Production steps of freeze dried Lactobacillus reuteri powder 1. Twenty ml of the fermentation medium is inoculated with 0.6 ml of freeze-dried Lactobacillus reuteri powder from a working cell bank vial. The fermentation is performed in a bottle at 37 C for 18 ¨20 hours without stirring or pH control i.e. static.
2. Two 1-liter flasks of the fermentation medium are inoculated with 9 ml cell slurry (from step 1) per liter of medium. The fermentation is performed at 37 C for 20 ¨22 hours without stirring or pH control i.e. static.
3. The two one liter cell slurries from step no. 2 are used to inoculate the 600-liter vessel containing 600 liters fermentation medium. The fermentation is performed at 37 C for 13 hours with stirring and pH control. At the start of the fermentation the pH
is 6.5. The pH
control starts when the pH drops below 5.4 using a 20% sodium hydroxide solution. The pH
control is set to pH 5.5.
4. The fourth and final fermentation step is performed in a 15,000-liter vessel with the inoculation from step no. 3. The fermentation is performed at 37 C for 9 to 12 hours with stirring and pH control. At the start of the fermentation the pH is 6.5. The pH control starts when the pH drops below 5.4 using a 20% sodium hydroxide solution. The pH
control is set to pH 5.5. 100 mM glycerol is added in the final phase of the fermentation, just before the culture reaches the stationary phase. The fermentation is complete when the culture reaches the stationary phase, which can be seen by the reduction of the addition of the sodium hydroxide solution. Roughly 930 liters of the sodium hydroxide solution is added to the 10,200 liters of media and 600 liters of inoculum during the fermentation.
The cell slurry from the final fermentation (step 4) is separated at 10 C
twice in a continuous centrifuge from Alfa Laval. By the first centrifugation the volume of the cell slurry is reduced from roughly 11,730 liters to 1200 liters. This volume is washed with 1200 liters of a peptone (Peptone 0-24, Orthana) solution in a 3000-liter vessel and is separated again before the mixing with the cryoprotectants (see below). The washing step with peptone is performed to avoid any freezing-point reduction in the freeze-drying process.
By the second centrifugation the volume of the cell slurry is reduced to 495 liters. This volume is mixed with 156 kg of the cryoprotectant solution to reach roughly 650 liters of the cell slurry.
The cell slurry is pumped to a 1000-liter vessel. The vessel is then transported to the freeze-drying plant.
At the freeze-drying plant, exactly 2 liters of the cell slurry is poured on each plate in the freeze dryer. The maximum capacity of the freeze dryer is 600 liters and all excessive cell slurry volume is thrown away.
The cell slurry of Lactobacillus reuteri has a dry matter content of 18 % and is freeze dried for four to five days.
During the freeze-drying process, the pressure in the process is between 0.176 mbar and 0.42 mbar. The vacuum pump is started when the pressure reaches 0.42 mbar.
The PRT
(pressurizing test) is used to determine when the process is complete. If the PRT or the increase of pressure is less then 0.02 mbar after 120 seconds, the process is stopped.
Combination of 1,2-PD and galactose generates a synergistic effect enhancing the activity of L. reuteri L. reuteri DSM 17938 was grown in modified MRS broth (with no glucose and citrate) with addition of 1,2-PD (0.3%), galactose (0.3%) or a combination of the two. The bacteria were grown for 24 h at 37 C. L. reuteri grown in the presence of both 1,2-PD and galactose surprisingly showed a significantly higher growth than the growth on the separate substances as seen in figure 1.
Example of shuttle program to be fed Thanks to the enhanced activity of L. reuteri induced by the SSCs described in this application it is possible to alternate the sachets of example 1 (sachet A) with sachets where L.
reuteri is excluded but otherwise manufactured according to example 1 (sachet B) in a shuttle program. This shuttle program does not reduce the efficiency of L. reuteri and may lower the treatment cost.
Sachet A is administered to the recipient at day 1, at day 2 and 3 the recipient is given sachet B. This administration scheme is repeated during the whole treatment period.
Intestinal colonization in vivo in humans A comparison between the intestinal colonization by L. reuteri alone and the same L.
reuteri administered together with SSC is made in a clinical study. 12 healthy volunteers are divided into two groups (A and B) with 6 participants in each group. Group A
receives the powder sachets of example 1, containing a composition of L. reuteri together with SSCs in the form of pectin, rhamnose and galacto-oligosaccharides. Group B receives the same L. reuteri strain but none of the above SSCs. Both groups are given 10E+8 CFU of L.
reuteri per day during 60 days. The quantitative evaluation of intestinal colonization by strains given alone or together with the SSCs is made by fecal sample examination at the beginning of the study, and after 30 and 60 days of the treatment period. Fecal L. reuteri is counted and the fecal amounts of group A and B are compared.
A significant increase in the fecal amounts of L. reuteri is seen in patients where L.
reuteri is administered together with SSCs, compared to patients where L.
reuteri is administered alone, as seen in table 1. The values are given as the average logio CFU per gram of feces SEM.
Table 1 study group L. reuteri count (n) before day 30 day 60 group A (6) N.D. 5.5 0.2 5.8 0.3 group B (6) N.D. 4.2 0.3 4.5 0.4
Claims (17)
1. A method for enhancing the activity of probiotic bacteria having a pdu-operon, in the gastrointestinal tract of an individual, comprising administering a substance to said individual, which substance has the capacity to be metabolized to 1,2-propanediol in the gastrointestinal tract of said individual.
2. The method of claim 1, wherein said substance comprises (a) rhamnose, (b) fucose, (c) pectin having a high percentage of rhamnose, (d) rhamnose in combination with pectin, (e) fucose in combination with pectin, (f) fucoidan having a high percentage of fucose, or (g) a combination of rhamnose, fucose and pectin.
3. The method of claim 1 or 2, wherein the substance is administered simultaneously with bacteria having a pdu operon.
4. The method of any preceding claim, wherein the bacteria having the pdu-operon comprise Lactobacilllus reuteri.
5. The method of any preceding claim, wherein the substance is administered to the individual at a daily dose of 0.25-25 g, preferably 1-2 g.
6. The method of any preceding claim, further comprising simultaneously administering a galactooligosaccharide or other saccharides comprising galactose.
7. A substance for use in enhancing the activity or increasing the growth of probiotic bacteria having a pdu-operon, in the gastrointestinal tract of an individual, which substance comprises a deoxy sugar that has the capacity to be metabolized to 1,2-propanediol in the gastrointestinal tract of said individual.
8. The substance of claim 7 comprising (a) rhamnose, (b) fucose, (c) pectin having a high percentage of rhamnose, (d) rhamnose in combination with pectin, (e) fucose in combination with pectin, (f) fucoidan having a high percentage of fucose, or (g) a combination of rhamnose, fucose and pectin.
9. The substance of any one of claims 7-8 wherein the bacteria having the pdu-operon are Lactobacilllus reuteri.
10. The substance of any one of claims 7-9, which is administered to the individual at a daily dose of 0.25-25 g, preferably 1-2 g.
11. The substance of any one of claims 7-10, which is for use in combination with galactooligosaccharides or other saccharides comprising galactose.
12. A composition comprising bacteria having a pdu-operon and a substance comprising a deoxy sugar, which deoxy sugar has the capacity to be metabolized to 1,2-propanediol in the gastrointestinal tract of an individual.
13. The composition of claim 12, which comprises bacteria having a pdu-operon, in combination with (a) rhamnose, (b) fucose, (c) pectin having a high percentage of rhamnose, (d) rhamnose in combination with pectin, (e) fucose in combination with pectin, (f) fucoidan having a high percentage of fucose, or (g) a combination of rhamnose, fucose and pectin.
14. The composition of claim 12 or 13, further comprising galactooligosaccharides or other saccharides comprising galactose.
15. The composition of any one of claims 12-14 wherein the bacteria having the pdu-operon are Lactobacilllus reuteri.
16. The composition of any one of claims 12-15 wherein the substance is present in an amount such as to give a daily dose of 0.25-25 g, preferably 1-2 g.
17. The composition of any one of claims 12-16 for use in enhancing the activity or increasing the growth of probiotic bacteria having a pdu-operon, in the gastrointestinal tract of an individual.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161463846P | 2011-02-23 | 2011-02-23 | |
| US61/463,846 | 2011-02-23 | ||
| US201161517130P | 2011-04-14 | 2011-04-14 | |
| US61/517,130 | 2011-04-14 | ||
| US13/400,735 | 2012-02-21 | ||
| US13/400,735 US20120263696A1 (en) | 2011-04-14 | 2012-02-21 | Indirect Substrates for Microorganisms Metabolizing 1,2-Propanediol |
| PCT/SE2012/050202 WO2012115588A1 (en) | 2011-02-23 | 2012-02-23 | Indirect substrates for microorganisms metabolizing 1,2-propanediol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2828072A1 true CA2828072A1 (en) | 2012-08-30 |
Family
ID=48782680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2828072A Abandoned CA2828072A1 (en) | 2011-02-23 | 2012-02-23 | Indirect substrates for microorganisms metabolizing 1,2-propanediol |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2677886A4 (en) |
| JP (1) | JP2014513058A (en) |
| KR (1) | KR20130140812A (en) |
| CN (1) | CN103402377A (en) |
| AU (1) | AU2012221154B2 (en) |
| BR (1) | BR112013020695A2 (en) |
| CA (1) | CA2828072A1 (en) |
| MX (1) | MX2013009650A (en) |
| RU (1) | RU2013142920A (en) |
| SG (1) | SG191355A1 (en) |
| WO (1) | WO2012115588A1 (en) |
| ZA (1) | ZA201304704B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4056052A1 (en) * | 2021-03-12 | 2022-09-14 | Biogaia AB | Gos pre-conditioning l. reuteri and gos in final formulation |
| EP4056053A1 (en) * | 2021-03-12 | 2022-09-14 | Biogaia AB | Pre-conditioning of l. reuteri |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3587219B2 (en) * | 1995-04-20 | 2004-11-10 | アサマ化成株式会社 | Food preservatives |
| AP9701167A0 (en) * | 1996-01-05 | 1998-01-31 | Hyprotech Pty Limited | Preserving soya beans for human consumption. |
| DE19836339B4 (en) * | 1998-08-11 | 2011-12-22 | N.V. Nutricia | carbohydrate mix |
| ATE423475T1 (en) * | 2001-11-12 | 2009-03-15 | Mars Inc | FOOD FOR CATS AND DOGS |
| JP2005537236A (en) * | 2002-06-13 | 2005-12-08 | ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク | Probiotic treatment |
| FR2844453B1 (en) * | 2002-09-13 | 2006-05-19 | Agronomique Inst Nat Rech | USE OF PRE-BIOTICS FOR PREVENTING THE INSTALLATION OF TYPE II DIABETES |
| ATE483366T1 (en) * | 2005-11-14 | 2010-10-15 | Unilever Nv | EDIBLE PRODUCT CONTAINING GINSENG POLYSACCHARIDES AND HEALTHY BACTERIA |
| NL1033521C2 (en) * | 2007-03-08 | 2008-09-09 | Friesland Brands Bv | Children's foods with optimized amino acid composition. |
| EP2143341A1 (en) * | 2008-07-08 | 2010-01-13 | Nestec S.A. | Nutritional Composition Containing Oligosaccharide Mixture |
| US8617537B2 (en) * | 2008-06-10 | 2013-12-31 | Biogaia Ab | Controlled activation of the reuterin-production machinery of lactobacillus |
| MX2011004142A (en) * | 2008-11-03 | 2011-05-25 | Nestec Sa | A nutritional composition comprising probiotics and improving sleep patterns. |
| ATE489856T1 (en) * | 2009-01-06 | 2010-12-15 | Rosebud Ag | SYMBIOTIC COMPOSITION AND ITS PRODUCTION PROCESS |
| AU2010281534B2 (en) * | 2009-07-27 | 2014-10-16 | Société des Produits Nestlé S.A. | Nutritional compositions comprising fiber and probiotics |
| CN101671399B (en) * | 2009-10-10 | 2011-05-11 | 山东大学威海分校 | Preparation method of fucoidan sulfuric ester with high purity and high-sulfate radical content |
-
2012
- 2012-02-23 BR BR112013020695A patent/BR112013020695A2/en not_active IP Right Cessation
- 2012-02-23 CN CN2012800099181A patent/CN103402377A/en active Pending
- 2012-02-23 SG SG2013049101A patent/SG191355A1/en unknown
- 2012-02-23 MX MX2013009650A patent/MX2013009650A/en unknown
- 2012-02-23 KR KR1020137017242A patent/KR20130140812A/en not_active Application Discontinuation
- 2012-02-23 EP EP12749453.2A patent/EP2677886A4/en not_active Withdrawn
- 2012-02-23 WO PCT/SE2012/050202 patent/WO2012115588A1/en active Application Filing
- 2012-02-23 AU AU2012221154A patent/AU2012221154B2/en not_active Ceased
- 2012-02-23 RU RU2013142920/10A patent/RU2013142920A/en not_active Application Discontinuation
- 2012-02-23 JP JP2013555393A patent/JP2014513058A/en active Pending
- 2012-02-23 CA CA2828072A patent/CA2828072A1/en not_active Abandoned
-
2013
- 2013-06-24 ZA ZA2013/04704A patent/ZA201304704B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ613318A (en) | 2015-10-30 |
| CN103402377A (en) | 2013-11-20 |
| MX2013009650A (en) | 2013-09-26 |
| KR20130140812A (en) | 2013-12-24 |
| ZA201304704B (en) | 2014-09-25 |
| AU2012221154A1 (en) | 2013-07-18 |
| BR112013020695A2 (en) | 2016-10-25 |
| EP2677886A1 (en) | 2014-01-01 |
| JP2014513058A (en) | 2014-05-29 |
| RU2013142920A (en) | 2015-03-27 |
| AU2012221154B2 (en) | 2015-12-10 |
| EP2677886A4 (en) | 2015-09-02 |
| WO2012115588A1 (en) | 2012-08-30 |
| SG191355A1 (en) | 2013-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1613180B1 (en) | Synbiotic combination | |
| KR101493302B1 (en) | Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same | |
| EP3345606A1 (en) | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract | |
| MX2012004778A (en) | Nutritional composition for promoting gut microbiota balance and health. | |
| WO2009008717A1 (en) | Use of probiotics and fibers for diarrhoea | |
| TW201542216A (en) | Novel lactobacillus paracasei strain | |
| US20120263696A1 (en) | Indirect Substrates for Microorganisms Metabolizing 1,2-Propanediol | |
| CN115944665A (en) | Probiotic agent for improving intestinal flora balance and preparation method and application thereof | |
| Staka et al. | Impact of oat-based products on human gastrointestinal tract | |
| US20140065696A1 (en) | Immunomodulatory Properties of Lactobacillus Strains | |
| AU2012221154B2 (en) | Indirect substrates for microorganisms metabolizing 1,2-propanediol | |
| KR20040037011A (en) | Food Composition Containing a Lactic Acid Bacteria | |
| KR20160113867A (en) | Composition for improving constipation and health food prepared thereof | |
| KR101779719B1 (en) | Novel Lactobacillus kefiranofaciens DN1 and composition for treating or preventing constipation comprising the same | |
| NZ613318B2 (en) | Indirect substrates for microorganisms metabolizing 1,2-propanediol | |
| KR102687185B1 (en) | A composition as a prebiotic for improving intestinal microflora containing polygalacturonic acid | |
| CN112237287B (en) | Lactobacillus rhamnosus LR519 capable of relieving constipation and composition thereof | |
| EP4151222A1 (en) | Composition for optimizing urolithin production in a human subject | |
| Biedrzycka | Microecosystem of the large intestine as a target-place for probiotics and prebiotics used as functional compounds of diet-a review. | |
| WO2024126577A1 (en) | Synthetic composition comprising a human milk oligosaccharide for microbiota modulation | |
| CN116583187A (en) | Composition for promoting accelerated butyrate production in young children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20180223 |